<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancer</dc:title><dc:creator>Borštnar,	Simona	(Avtor)
	</dc:creator><dc:creator>Čufer,	Tanja	(Avtor)
	</dc:creator><dc:creator>Vrhovec,	Ivan	(Avtor)
	</dc:creator><dc:creator>Rudolf,	Zvonimir	(Avtor)
	</dc:creator><dc:description>Urokinase plasminogen activator (uPA) and its inhibitors, PAI-1 and PAI-2, play an important role in iritercellular tissue degradation, thus promoting tumor cell invasion into the adjoining structures and metastasizing. Our studywas aimed to assess a possible prognostic value of uPA, PAI-1 and PAI-2 in a retrospective series of 87 patients with breast cancer stage I-III, whosecytosols were stored in the archives of the, Institute of Oncology in Ljubljana. The median follow-up was 35 months. The prognostic value of the established prognostic factors and uPA, PAI-1 and PAI-2 were evaluated by means of univariate statistical analysis and partial multivariate models. The obtained uPA values were very low and did not correlate with the disease free survival, whereas PAI-1 and PAI-2 significantly influenced the time to the first recurrence. Patients with PAI-1 values above 5 ng/mg proteins had statistically significantly worse disease free survival than the patients withlower PAI-1 values (58% vs. 85%). In the case of PAI-2, the situation wasjust the opposite: the patients with PAI-2 values exceeding 6.4 ng/mg proteins had statistically significantly better 3-year disease free survival than the patients with lower values (90% vs. 60%). Both, PAI-1 and PAl-2 retained their independent prognostic value, irrespective of the addition of the established prognostic factors to partial multivariate models, and only with locally advanced disease the prognostic value of PAI-1 was greater than that of PAI-2.</dc:description><dc:publisher>Slovenian Medical Association - Slovenian Association of Radiology, Nuclear Medicine Society, Slovenian Society far Radiotherapy and Oncology, and Slovenian Cancer Society </dc:publisher><dc:date>1999</dc:date><dc:date>2024-01-22 10:45:47</dc:date><dc:type>Neznano</dc:type><dc:identifier>17910</dc:identifier><dc:identifier>UDK: 616-006</dc:identifier><dc:identifier>ISSN pri članku: 1318-2099</dc:identifier><dc:identifier>COBISS_ID: 9752281</dc:identifier><dc:source>Ljubljana</dc:source><dc:language>sl</dc:language><dc:rights>by Authors</dc:rights></metadata>
